Latest news about Hikal
Hikal
252.89
+8.72(+3.57%)
Company Performance:
View Company Insights1D+3.57%
1M+5.22%
6M-33.27%
1Y-42.71%
5Y+47.46%
More news about Hikal
21Aug 25
Hikal Receives US FDA Warning Letter for Bengaluru Manufacturing Facility
Hikal Limited, an Indian pharmaceutical company, has received a warning letter from the US FDA regarding its Jigani, Bengaluru manufacturing facility. The warning follows an inspection conducted from February 3-7, 2025. Hikal has committed to addressing the regulatory concerns and working closely with the FDA to resolve the issues. The company's credit ratings have been reaffirmed by ICRA Limited, with a long-term rating of ICRA A+ (Stable) and a short-term rating of ICRA A1.
13Aug 25
Hikal Limited Reports Revenue Decline in Q1 Amid Regulatory Challenges
Hikal Limited's Q1 consolidated revenue decreased to Rs. 380.00 crores from Rs. 407.00 crores year-on-year. EBITDA fell to Rs. 25.00 crores with margins contracting to 6.50%. The pharmaceutical division saw an 11.70% revenue decline to Rs. 203.00 crores, reporting an EBIT loss of Rs. 27.00 crores due to deferred shipments following US FDA's OAI status for its Bangalore facility. The crop protection division remained stable with Rs. 178.00 crores revenue. Despite challenges, the company maintains its annual guidance and is implementing strategic initiatives including capacity expansion, dual-site manufacturing, and diversification into personal care products.
07Aug 25
HIKAL Reports Q1 Net Loss of ₹224 Million Amid Revenue Decline
Hikal Limited reported a net loss of ₹224.00 million in Q1, compared to a profit of ₹51.00 million in the same quarter last year. Revenue decreased by 6.5% to ₹3,804.00 million from ₹4,068.00 million year-over-year. EBITDA fell to ₹251.00 million from ₹580.00 million, with the EBITDA margin compressing to 6.60% from 14.26%. The Pharmaceuticals segment generated revenue of ₹2,026.00 million, while the Crop Protection segment contributed ₹1,778.00 million.
30Jul 25
Hikal's Jigani Unit Secures GMP Certification from Japan's PMDA
Hikal Limited's Jigani Unit in Bangalore has received Good Manufacturing Practices (GMP) certification from Japan's Pharmaceutical and Medical Device Agency (PMDA) for Active Pharmaceutical Ingredients (APIs). The certification was granted after a four-day inspection from May 19th to 22nd. This achievement could open doors to the Japanese pharmaceutical market and enhance Hikal's global credibility. The company officially informed stock exchanges about this development on July 30th.
17Jun 25
Hikal's Jigani Unit Passes Brazilian Anvisa GMP Audit
Hikal Limited's Jigani facility successfully passed a Good Manufacturing Practice (GMP) audit conducted by Brazilian Anvisa, Brazil's health regulatory agency. This achievement signifies compliance with Brazilian regulatory standards and could potentially open new opportunities for Hikal in the Brazilian pharmaceutical market. The approval aligns with Hikal's strategy to strengthen its position in the global pharmaceutical supply chain and demonstrates its ability to meet international regulatory requirements.
16Jun 25
Hikal's Jigani Facility Passes Brazilian ANVISA GMP Audit
Hikal Ltd successfully completed a Good Manufacturing Practice (GMP) audit by ANVISA, Brazil's regulatory authority, for its Jigani facility. This approval enhances Hikal's global credibility, opens opportunities for expansion in the Brazilian pharmaceutical market, and demonstrates the company's operational excellence. The ANVISA certification is expected to strengthen Hikal's position in the global pharmaceutical manufacturing landscape and may lead to increased collaborations with Brazilian and multinational pharmaceutical companies.
26May 25
Hikal's Jigani Facility Faces FDA Scrutiny with 'Official Action Indicated' Classification
Hikal Ltd. announced that its Jigani, Karnataka manufacturing facility has been classified as 'Official Action Indicated' (OAI) by the U.S. FDA following an inspection. This classification suggests significant issues were identified, potentially leading to regulatory actions. Hikal has committed to working closely with the FDA to resolve the issues and emphasized its ongoing efforts to enhance compliance measures. The OAI status could potentially impact new product approvals and existing product supply from this facility.
23May 25
Hikal's Jigani Facility Faces FDA Scrutiny with 'Official Action Indicated' Classification
Hikal Ltd's Jigani facility has been classified as 'Official Action Indicated' (OAI) following a U.S. FDA inspection, indicating significant objectionable conditions. The company has committed to addressing the FDA's concerns, working closely with the agency to resolve issues, and maintaining high-quality manufacturing standards. This classification may lead to increased regulatory scrutiny, require remediation efforts, and potentially impact new product approvals or existing product shipments from the facility.
14May 25
HIKAL's Q4 Results Showcase Robust Financial Growth
HIKAL Limited, a specialty chemicals and pharmaceuticals manufacturer, reported impressive Q4 financial results. EBITDA increased by 30.16% to 1.23 billion rupees, with EBITDA margin expanding to 22.34%. Consolidated net profit surged by 47.65% to 502 million rupees. The company demonstrated significant year-over-year improvements across key financial metrics, indicating strong operational efficiency and market positioning.
Industry Peers
Windlas Biotech
Jeena Sikho Lifecare
Valiant Laboratories
Blue Jet Healthcare
Abbott
Sunrest Lifescience
Zenith Drugs
Pfizer
FDC
Medicamen Organics
790.15
(+0.55%)
699.20
(+0.52%)
64.57
(-0.75%)
554.80
(-2.56%)
28,850.00
(-0.14%)
42.05
(-2.21%)
54.60
(+2.25%)
5,001.00
(+0.57%)
414.10
(+0.24%)
26.95
(0.0%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
